The designation allows Diakonos to expedite development and review of the organization’s dendritic cell vaccine technology for pancreatic cancer, according to a July 15 news release from the company. Diakonos has also applied the DCV technology to a vaccine for treating glioblastoma.
Daniel Von Hoff, MD, has been named to the Diakonos’ scientific advisory board and will advise the clinical development process of the pancreatic cancer vaccine.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
